BY ACCESSING AMERICANMIGRAINEFOUNDATION.ORG, YOU AGREE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW THAT YOU WILL HOLD AMGEN INC. AND ITS AFFILIATES ARE NOT RESPONSIBLE FOR AND EXPRESSLY DISCLAIM ALL LIABILITY, INCLUDING WITHOUT LIMITATION, FOR DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, AND SPECIAL OR OTHER DAMAGES ARISING FROM OR RELATED TO THE USE OF ANY SERVICES OFFERED BY AMERICANMIGRAINEFOUNDATION.ORG. TO THE MAXIMUM EXTENT PERMITTED BY LAW, AMGEN INC. MAKES NO EXPRESS, IMPLIED OR STATUTORY WARRANTIES OR REPRESENTATIONS (INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE) AMERICANMIGRAINEFOUNDATION.ORG. has not entered into any agreement with any doctor affiliated with to render any treatment or care to any patient, and has not evaluated the credentials, experience or expertise of any physician affiliated with, or referred through,. is an independent entity, and not affiliated with, or an agent of, Amgen Inc.Patients should discuss the risks and benefits of any procedure with their physician.Patients should discuss with their physician their experience with the patient’s medical condition and should then determine if the physician is qualified to perform the procedure.Access to is not intended to provide medical advice or a referral to a particular physician.Amgen & Novartis are not responsible for and do not endorse or control the content contained on this third-party website. Parsippany, NJ: Teva Pharmaceuticals USA, Inc.You are about to leave the website and enter a website operated by a third party. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Blumenfeld AM, Stevanovic DM, Ortega M, et al. North Wales, PA: Teva Pharmaceuticals USA, Inc. References: 1. AJOVY ® (fremanezumab-vfrm) injection Current Prescribing Information. When asked, “Was the autoinjector easy to use?”, 97% in study 1 (N=30) and 98% in study 2 (N=47) answered “Yes.” 4ĬGRP: calcitonin gene-related peptide SC: subcutaneous. ![]() §Two human factor studies assessed evaluators’ ability to complete critical tasks in order to demonstrate use of the AJOVY Autoinjector in simulated-use sessions. ‡Inadequate response to a prior medication was defined as: (1) no clinically meaningful improvement after at least 3 months (2) patient could not tolerate the drug (3) drug was contraindicated for patient or (4) drug was not suitable for the patients. †Please see additional dosing information. Please see full Prescribing Information for AJOVY. IndicationĪJOVY is indicated for the preventive treatment of migraine in adults. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.Īdverse Reactions: The most common adverse reactions in clinical trials (≥5% and greater than placebo) were injection site reactions. Cases of anaphylaxis and angioedema have been reported in the postmarketing setting. ![]() Most reactions were reported from within hours to one month after administration. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Reactions have included anaphylaxis and angioedema. ![]() Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |